Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
SHANGHAI, Dec. 14, 2023 /PRNewswire/ -- The Japan-based Global Health Innovative Technology Fund (GHIT Fund) announced today that it will invest approximatelyUS$3.3 million (approximately 500 million yen[1]) in a global multicenter Phase III clinical trial project (the "Program") led by Fosun Ph...
Fosun Pharma Announces 2023 Interim Results: Continues to Promote Innovation Transformation and Optimizes Product Structure
SHANGHAI, Aug. 29, 2023 /PRNewswire/ -- On August 29, 2023, Shanghai Fosun Pharmaceutical Co., Ltd.* (Stock Code: 600196.SH; 02196.HK) announced its 2023 Interim Results for the first half of 2023. (the "Reporting Period"). During the Reporting Period, Fosun Pharma achieved revenue ofRMB21.395 bi...
Fosun Pharma Participates in 2023 BIO International Convention to Demonstrate its Global Innovation Capabilities
BOSTON, June 6, 2023 /PRNewswire/ -- From June 5th to 8th (Pacific Standard Time), the 2023 BIO International Convention ("BIO 2023") will be held in Boston, Massachusetts, USA. The BIO International Convention is the world's largest gathering of the biotechnology industry along with industry-lead...
Fosun Pharma and IFC Partner to Improve Access to High Quality Medicines in Africa
ABIDJAN, Côte d'Ivoire, June 6, 2023 /PRNewswire/ -- To support stronger healthcare delivery and outcomes inWest Africa, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma or the Company, stock code: 600196.SH; 02196.HK) today announced a deepening partnership with IFC to help the comp...
Fosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements
MACAU, May 10, 2023 /PRNewswire/ -- From May 10 to 12, 2023, the 3rd BEYOND International Technology Innovation Expo — also known as BEYOND Expo 2023is being held at the Venetian Macau Convention and Exhibition Center. This year is the third consecutive year that Fosun Pharma (stock code: 600196....
Fosun Pharma Develops Innovative Artemisinin-based Antimalarial Drugs Contributing to the Efforts for A Malaria-free World Through the Belt and Road Initiative
SHANGHAI, April 26, 2023 /PRNewswire/ -- On April 25, 2023, World Health Organization (WHO) gave as the theme for World Malaria Day 2023 Time to deliver zero malaria: invest, innovate, implement. Within this theme, WHO will mainly focus on the third "i" – implement – and notably the critical imp...
Fosun Pharma Announces its 15th Corporate Social Responsibility Report: Continuous Innovation for the Benefit of the Public
SHANGHAI, March 29, 2023 /PRNewswire/ -- On March 27, 2023, the release date of its 2022 Annual Report, Fosun Pharma (stock code: 600196.SH; 02196.HK) also released the2022 Corporate Social Responsibility Report, its 15th CSR report since the first which was issued in 2009. As before, Fosun Pharm...
Fosun Pharma Announces 2022 Annual Results: Achieved Steady Growth with Revenue from Record High Innovative Products and Global Commercialization Capability Improvement
Performance Highlights: * During the reporting period, the revenue was RMB 43.952 billion, with a year-on-year growth of12.66%; the net profit after deducting extraordinary gain or loss attributable to owners of the parent wasRMB 3.873 billion, with a year-on-year growth of 18.17%; * The rev...
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US
PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab inth...
Comirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents
SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original/Omicron BA.4/BA.5 bivalent vaccine (i.e. Comirnaty Original/Omicro...
Fosun Pharma's MSCI ESG Rating Upgraded to A
SHANGHAI, Oct. 13, 2022 /PRNewswire/ -- The world's leading index company Morgan Stanley Capital International ("MSCI") recently announced its latest annual Environmental, Social and Governance ("ESG") rating results. In recognition of its outstanding performance in ESG,MSCI upgraded the ESG rati...
Fosun Pharma and MAIA Pharmaceuticals Jointly Announce the Successful Commercialization of Only FDA Approved 20ml Sodium Phenylacetate and Sodium Benzoate (SPSB) Liquid Product
PRINCETON, N.J., Sept. 26, 2022 /PRNewswire/ -- Shanghai Fosun Pharma (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced that the 20 ml, Sodium Phenylacetate and Sodium Benzoate (SPSB) liquid product, which is under an exclusive partnership betweenFosun Pharma USA...
Fosun Pharma Announces 2022 Interim Results
Stable Revenue Growth and Recurring Income, Elevating the Revenue Contribution of New Products, and Accelerating International Layout Highlights: * Revenue for the first half of 2022 amounted to RMB21,340 million, an increase of 25.88% YOY; * Net profit (after extraordinary gain or loss) att...
World Malaria Day: Fosun Pharma's Self-Developed Artemisinin Series Become Symbol of China's Innovative Medicines
Together We Build a Malaria-Free World SHANGHAI, April 25, 2022 /PRNewswire/ -- World Malaria Day on April 25, is an occasion that aims to promote global malaria prevention and control. This year, World Malaria Day is marked under the theme "Harness innovation to reduce the malaria disease burde...
Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control
SHANGHAI, April 14, 2022 /PRNewswire/ -- April 13, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK) announced that the Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) self-developed by Fosun Diagnostics Co....
Fosun Pharma 2021 Annual Results Announcement: Accelerating the Globalization Comprehensively
The Proportion of Revenue from Innovative Products Continues to Increase Highlights: * Revenue for the year ended December 31, 2021 was RMB39,005 million, representing an increase of 28.70% YOY; * The proportion of revenue from new products as well as regions outside Mainland China and count...
Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets
SHANGHAI and NEW YORK, Jan. 11, 2022 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading innovation-driven international healthcare group inChina and Insilico Medicine ("Insilico"), an end-to-end artificial intelligence (AI)...
Fosun Pharma Announces 2020 Annual Results
Multiple Innovative Products Launched with Significant Improvement in the Capability of Global Commercialization Net Profit Attributable to Shareholders After Extraordinary G/L Increases 21.65% YOY toRMB2,718 Million SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (...
BioNTech and Fosun Pharma Receive Authorization for Emergency Use in Hong Kong for COVID-19 Vaccine
MAINZ, Germany and SHANGHAI, China, 25 Jan. 2021 /PRNewswire/ -- BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") andShanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) today announced that according to the Food and Health Bureau of ...
Fosun Pharma Announces 2020 Interim Results
SHANGHAI, Aug. 26, 2020 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK), a leading healthcare group inChina, announced its interim results for the year 2020 ("the Reporting Period"). During the Reporting Period： * The revenue ac...
